- Phase 2 stage of its Phase 1b/2 clinical trial of AST-008 is still expected to begin in 2nd quarter - Research labs open for critical R&D activity; progress continues on Friedreich’s Ataxia development and collaboration programs - Preliminary unaudited cash, cash equivalents, and short-term investments as of February 29,… Read More..

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it has signed a letter of intent ("LOI") to partner with WorldCare Clinical, LLC for the Company’s rheumatoid arthritis ("RA") diagnostic clinical imaging workflow. Per… Read More..

PRINCETON, N.J., March 30, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31,… Read More..